{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:57:59Z","timestamp":1774382279996,"version":"3.50.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2020R1A2B5B01001859"],"award-info":[{"award-number":["NRF-2020R1A2B5B01001859"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Fecal calprotectin (FC) is widely used for the diagnosis and monitoring disease activity of inflammatory bowel disease (IBD). Quantitative rapid assays can be a reliable alternative to the time-consuming assay. This study aimed to evaluate and compare the diagnostic performance of two quantitative rapid FC assays (Ichroma calprotectin, and Buhlmann Quantum blue).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 192 patients were included in this study; 84 patients with IBD (67 ulcerative colitis and 17 Crohn\u2019s disease) and 108 patients with non-IBD. We compared quantitative FC levels in different disease statuses and evaluated the correlation between the FC results of the two FC kits. Diagnostic performances in predicting active IBD were evaluated in reference to different cut-off levels.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The FC levels in 45 patients with active IBD as defined by endoscopic score were significantly higher compared to the inactive IBD and other diseases (<jats:italic>P<\/jats:italic>&lt;0.05). Although the two assays\u2019 results correlated (r = 0.642, P &lt; 0.001), a significant deviation was observed (y (Buhlmannn) = -45.2 +8.9X (Ichroma)). The Diagnostic performances in predicting active IBD were comparable as area under the curve (AUC), 0.812, cut-off, 50, sensitivity, 64.4%, and specificity, 85.0% for iChroma assay and AUC, 0.826, cut-off, 100, sensitivity, 84.4%, and specificity 61.9% for Buhlmann Quantum Blue assay. FC levels using a cut-off of &gt; 250 \u03bcg\/g confirmed 85.7% (iChroma) and 64.1% (Buhlmann) of active IBD patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The results of the two rapid FC assays iChroma and Buhlmann showed a significant correlation, but the two test results were not interchangeable. With optimized cut-off values, rapid FC tests could be helpful in the diagnosis of IBD and differentiating active IBD from inactive or organic bowel disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0255974","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T18:54:15Z","timestamp":1628794455000},"page":"e0255974","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-5285","authenticated-orcid":true,"given":"Jong-Mi","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Hee","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyeong","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeeun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5870-915X","authenticated-orcid":true,"given":"Eun-Jee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"issue":"6","key":"pone.0255974.ref001","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1248\/bpb.26.753","article-title":"Calprotectin (S100A8\/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity.","volume":"26","author":"S Yui","year":"2003","journal-title":"Biological and Pharmaceutical Bulletin"},{"issue":"2","key":"pone.0255974.ref002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5217\/ir.2013.11.2.73","article-title":"Fecal biomarkers in inflammatory bowel disease.","volume":"11","author":"K-M Lee","year":"2013","journal-title":"Intestinal Research"},{"issue":"10","key":"pone.0255974.ref003","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ibd.20490","article-title":"Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn\u2019s disease.","volume":"14","author":"T Sipponen","year":"2008","journal-title":"Inflammatory bowel diseases."},{"issue":"11","key":"pone.0255974.ref004","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/ibd.22863","article-title":"Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents.","volume":"18","author":"P Molander","year":"2012","journal-title":"Inflammatory bowel diseases."},{"issue":"3","key":"pone.0255974.ref005","first-page":"673","article-title":"Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis","volume":"104","author":"G Ho","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"pone.0255974.ref006","doi-asserted-by":"crossref","first-page":"e0224895","DOI":"10.1371\/journal.pone.0224895","article-title":"Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.","volume":"14","author":"R Goll","year":"2019","journal-title":"PloS one."},{"issue":"10","key":"pone.0255974.ref007","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1515\/cclm-2016-1012","article-title":"Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease","volume":"55","author":"M Oyaert","year":"2017","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)."},{"issue":"11","key":"pone.0255974.ref008","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.cgh.2015.05.038","article-title":"Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis","volume":"13","author":"K Theede","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4","key":"pone.0255974.ref009","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1515\/cclm-2012-0386","article-title":"Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method","volume":"51","author":"L Coorevits","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"pone.0255974.ref010","first-page":"77","article-title":"Faecal calprotectin.","volume":"39","author":"WGW Pathirana","year":"2018","journal-title":"The Clinical Biochemist Reviews"},{"issue":"4","key":"pone.0255974.ref011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5217\/ir.2016.14.4.305","article-title":"Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease.","volume":"14","author":"HW Jang","year":"2016","journal-title":"Intestinal research."},{"issue":"1","key":"pone.0255974.ref012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/2050640613518201","article-title":"Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease","volume":"2","author":"D Labaere","year":"2014","journal-title":"United European Gastroenterology Journal"},{"issue":"Pt 1","key":"pone.0255974.ref013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1258\/acb.2011.011106","article-title":"Evaluation of the Quantum Blue\u00ae rapid test for faecal calprotectin","volume":"49","author":"J Wassell","year":"2012","journal-title":"Ann Clin Biochem"},{"issue":"1\u20132","key":"pone.0255974.ref014","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cca.2011.09.030","article-title":"Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin","volume":"413","author":"A Dolci","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"1","key":"pone.0255974.ref015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3343\/alm.2020.40.1.68","article-title":"Evaluating Diagnostic Tests for Helicobacter pylori Infection Without a Reference Standard: Use of Latent Class Analysis.","volume":"40","author":"DW Jekarl","year":"2020","journal-title":"Ann Lab Med."},{"issue":"1","key":"pone.0255974.ref016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3343\/alm.2019.39.1.50","article-title":"Performance Evaluation of the Automated Fluorescent Immunoassay System Rotavirus Assay in Clinical Samples.","volume":"39","author":"J-S Kim","year":"2019","journal-title":"Ann Lab Med."},{"issue":"5","key":"pone.0255974.ref017","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-018-4980-0","article-title":"Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis","volume":"63","author":"WY Mak","year":"2018","journal-title":"Digestive diseases and sciences"},{"issue":"1","key":"pone.0255974.ref018","first-page":"1","article-title":"Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis","volume":"17","author":"S-H Lee","year":"2017","journal-title":"BMC gastroenterology"},{"issue":"4","key":"pone.0255974.ref019","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/01.MIB.0000442681.85545.31","article-title":"Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.","volume":"20","author":"U Kopylov","year":"2014","journal-title":"Inflammatory bowel diseases."},{"issue":"6","key":"pone.0255974.ref020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/1319-3767.170948","article-title":"Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.","volume":"21","author":"L Kwapisz","year":"2015","journal-title":"Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association."},{"issue":"8","key":"pone.0255974.ref021","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ibd.20933","article-title":"Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.","volume":"15","author":"JP Gisbert","year":"2009","journal-title":"Inflammatory bowel diseases."},{"issue":"2","key":"pone.0255974.ref022","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.crohns.2009.09.008","article-title":"Does fecal calprotectin predict relapse in patients with Crohn\u2019s disease and ulcerative colitis?","volume":"4","author":"V Garc\u00eda-S\u00e1nchez","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"3","key":"pone.0255974.ref023","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn\u2019s disease","volume":"54","author":"F Costa","year":"2005","journal-title":"Gut"},{"issue":"10","key":"pone.0255974.ref024","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies.","volume":"18","author":"R Mao","year":"2012","journal-title":"Inflammatory bowel diseases."},{"issue":"10","key":"pone.0255974.ref025","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2036.2008.03835.x","article-title":"Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn\u2019s disease and histological findings","volume":"28","author":"T Sipponen","year":"2008","journal-title":"Alimentary pharmacology & therapeutics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T18:54:46Z","timestamp":1628794486000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255974"}},"subtitle":[],"editor":[{"given":"Hsu-Heng","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255974","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}